{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:39:37Z","timestamp":1776317977210,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00228-020-02957-2","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T23:04:48Z","timestamp":1599260688000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Doctor\u2019s aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center"],"prefix":"10.1007","volume":"77","author":[{"given":"Omar","family":"Al Tabaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Etcheto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Goulvestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"issue":"5","key":"2957_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nri2747","volume":"10","author":"A Beck","year":"2010","unstructured":"Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345\u2013352","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2957_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nbt.1944","volume":"29","author":"R Strohmeier","year":"2011","unstructured":"Strohmeier R, Draghia-Akli R, Rys A, Silvan PO, Lennon T, Incerti C, Bergstr\u00f6m R, Chibout S, Doliveux R, Andersen PH (2011) IMI moves forward. Nat Biotechnol 29(8):689\u2013691","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2957_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, Leszczy\u0144ski P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J (2017) A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 76(1):51\u201357","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2957_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1080\/19420862.2016.1193659","volume":"8","author":"IH Cho","year":"2016","unstructured":"Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z et al (2016) Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. mAbs 8(6):1136\u20131155","journal-title":"mAbs"},{"issue":"10","key":"2957_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ure\u00f1a S, Lim MJ, Lee YA, Lee SJ, Kim HU, Yoo DH, Braun J (2013 Oct) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605\u20131612","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2957_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"J-Y Choe","year":"2017","unstructured":"Choe J-Y, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH, Smolen JS (2017) A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 76(1):58\u201364","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2957_CR7","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/rheumatology\/kex254","volume":"56","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Choe J-Y, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH (2017) Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology. 56(10):1771\u20131779","journal-title":"Rheumatology."},{"issue":"10086","key":"2957_CR8","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, M\u00f8rk C, Jahnsen J, Kvien TK, Berset IP, Fevang BTS, Florholmen J, Kalstad S, M\u00f8rk NJ, Ryggen K, Tveit KS, S\u00e6ther SK, Gulbrandsen B, Hagfors J, Waksvik K, Warren D, Henanger KJ, Asak \u00d8, Baigh S, Blomgren IM, Bruun TJ, Dvergsnes K, Frigstad SO, Gjesdal CG, Grandaunet BHJ, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Kruse JR, Ljos\u00e5 MKA, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Presteg\u00e5rd U, Rashid HU, Rydning JH, Sagatun L, Seeberg KA, Skjetne K, Strand EK, Stray H, Stray N, Torp R, Vold C, Ystr\u00f8m CM, Zettel CC (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389(10086):2304\u20132316","journal-title":"Lancet"},{"issue":"8","key":"2957_CR9","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, S\u00f8rensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydeh\u00f8j J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, S\u00f8rensen MV, Andersen LS, Gr\u00f8n KL, Krogh NS, Pedersen L, Hetland ML (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76(8):1426\u20131431","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2957_CR10","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","volume":"15","author":"E Nikiphorou","year":"2015","unstructured":"Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, Sokka T (2015) Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 15(12):1677\u20131683","journal-title":"Expert Opin Biol Ther"},{"key":"2957_CR11","doi-asserted-by":"crossref","unstructured":"Tweehuysen L, Huiskes VJ, van den Bemt BJ, Vriezekolk JE, Teerenstra S, van den Hoogen FH, et al. Open-label non-mandatory transitioning from originator etanercept to biosimilar SB4: 6-month results from a controlled cohort study. Arthritis Rheumatol. 2018 Apr 2 [cited 2018 Apr 13]; Available from: http:\/\/doi.wiley.com\/10.1002\/art.40516","DOI":"10.1136\/annrheumdis-2018-eular.2592"},{"issue":"5","key":"2957_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","volume":"47","author":"J Avouac","year":"2018","unstructured":"Avouac J, Molt\u00f3 A, Abitbol V, Etcheto A, Salcion A, Gutermann L, Klotz C, Elhai M, Cohen P, Soret PA, Morin F, Conort O, Chast F, Goulvestre C, Jeunne CL, Chaussade S, Kahan A, Roux C, Allanore Y, Dougados M (2018) Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum 47(5):741\u2013748","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2957_CR13","first-page":"40","volume":"25","author":"RK Dore","year":"2007","unstructured":"Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P (2007) The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 25(1):40\u201346","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"2957_CR14","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, Leszczy\u0144ski P, Porawska W, Stasiuk B, Hilt J, Mosterova Z, Cheong SY, Ghil J (2017) Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis 76(12):1986\u20131991","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2957_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrugantibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents inchronic inflammatory diseases: a real issue, a clinical perspective. Ann RheumDis 72(2):165\u2013178","journal-title":"Ann RheumDis"},{"issue":"2","key":"2957_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, D\u00f6rner T, Emery P, Kvien TK, Smolen JS, Breedveld FC, Task Force on the Use of Biosimilars to Treat Rheumatological Diseases (2018) Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 77(2):165\u2013174","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2957_CR17","doi-asserted-by":"publisher","first-page":"e000141","DOI":"10.1136\/rmdopen-2015-000141","volume":"1","author":"D Skingle","year":"2015","unstructured":"Skingle D (2015) Biosimilars: what do patients need to consider? RMD Open 1(1):e000141","journal-title":"RMD Open"},{"key":"2957_CR18","doi-asserted-by":"crossref","unstructured":"Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet M-E, Bannwarth B et al (2017) Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Jt Bone Spine Rev Rhum 14","DOI":"10.1016\/j.jbspin.2017.10.003"},{"issue":"4","key":"2957_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","volume":"81","author":"A Frazier-Mironer","year":"2014","unstructured":"Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, le Lo\u00ebt X, Combe B (2014) Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Jt Bone Spine Rev Rhum 81(4):352\u2013359","journal-title":"Jt Bone Spine Rev Rhum"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02957-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02957-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02957-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T23:09:40Z","timestamp":1630796980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02957-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2957"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02957-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]},"assertion":[{"value":"10 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}